New formulation developed by Quatech scientists offers natural, effective care for chronic wounds with international patent filings underway
In a major scientific development, researchers at Quatech, the dedicated research center of Gorgio International Holding, have created a groundbreaking, fully organic treatment designed to accelerate the healing of chronic wounds including burns, diabetic foot ulcers, and pressure sores.
The formulation, which has already demonstrated promising results in early clinical applications, utilizes an innovative oil-based composition derived entirely from organic compounds. Its key functions include maintaining moisture balance, promoting epithelial regeneration, and stimulating localized blood flow — all crucial factors in advanced wound care.
According to Quatech’s research team, this development responds to a growing global need for effective, non-synthetic treatments in the management of complex skin injuries. Diabetic ulcers and bedsores represent a persistent burden on healthcare systems worldwide, particularly in aging and immunocompromised populations.
“Our innovation offers a safe, scalable solution to a long-standing clinical challenge,” said a Quatech spokesperson. “It’s designed for high efficacy without relying on synthetic chemicals or antibiotics, making it suitable even for vulnerable patient groups.”
The invention has undergone international review through the World Intellectual Property Organization (WIPO), where it was confirmed to meet key criteria of novelty, inventive step, and industrial applicability. National patent filings are now underway in major jurisdictions, including the United States and United Kingdom.
Photographic documentation of treatment stages has been compiled to support future clinical validation and transparent peer review. These records show marked improvement in wound closure and skin regeneration across various patient profiles.
Gorgio International Holding, which operates across Georgia and the UK, has positioned itself as an emerging leader in organic biopharmaceutical innovation. Through Quatech, the company is actively pursuing further research collaborations, institutional studies, and regulatory engagement to advance the technology’s global rollout.
